Actelion Ltd.
Gewerbestrasse 16
Allschwil
CH - 4123
Tel: 41-61-487-4545
Fax: 41-61-487-4507
Website: http://www.actelion.com/
139 articles with Actelion Ltd.
-
Arkivum Provides Pioneering e-Archive to Idorsia Pharmaceuticals Delivering GxP Compliant Long-term Access to Valuable Product and Clinical Trial Data
9/3/2019
Arkivum announced that Idorsia Pharmaceuticals, headquartered near Basel, Switzerland; has selected Arkivum to safeguard and digitally preserve their valuable research and clinical trial data.
-
The government alleged Actelion provided money to a nonprofit to cover copay costs for Medicare drugs, a violation of the False Claims Act.
-
Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma
3/21/2018
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma, a rare type of skin cancer.
-
Cancellation of Publicly Held Actelion Shares and Delisting From SIX Swiss Exchange as of November 7, 2017
10/31/2017
The holders of the cancelled Actelion Shares will be paid a cash compensation in the amount of $280 for each cancelled Actelion Share.
-
Actelion Receives FDA Approval Of TRACLEER (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
9/6/2017
-
Johnson & Johnson Completes Acquisition Of Actelion
6/16/2017
-
Johnson & Johnson Announces Completion Of Acquisition Of Actelion
6/16/2017
-
As Johnson & Johnson Closes $30 Billion Deal, Actelion Spinoff Is Valued at $1.54 Billion In IPO Debut
6/16/2017
-
Johnson & Johnson Announces Expected Settlement Of Actelion Tender Offer On June 16, 2017
6/9/2017
-
Actelion Reports Good And Bad News For Phase III CDAD Trials
6/8/2017
-
Actelion Provides An Update On The Progress Towards Launching Idorsia - Key Results For Pipeline Assets To Be Developed By Idorsia
5/22/2017
-
Actelion Announces Changes To Its Executive Team Upon Completion Of The Transaction With Johnson & Johnson
5/15/2017
-
Publication Of The Definitive Notice Of The End Result Of Actelion Tender Offer
4/27/2017
-
Publication Of The Provisional Notice Of The End Result Of Actelion Tender Offer
4/24/2017
-
Actelion's R&D Discovery Biz Gets a Name, Idorsia
3/15/2017
-
So Close, Yet So Far Away: How Sanofi Lost to Johnson & Johnson in the Epic $30 Billion Battle for Actelion
2/16/2017
-
Johnson & Johnson Publishes Prospectus For Actelion Tender Offer
2/16/2017
-
Despite Losing Out on Actelion, Sanofi in No Hurry to Make Deals
2/8/2017
-
It's Finally Happening: Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D Unit With $1 Billion Cash
1/27/2017
-
How a Johnson & Johnson Corporate Jet Had Hedge Funds Betting Big on an Actelion Deal
1/27/2017